VirionHealth Raises Series A Funding from Abingworth
VirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has raised up to £13 million in Series A funding from Abingworth, the international investment group dedicated to life sciences.
VirionHealth is a University of Warwick spinout company, set up with the support of Warwick Ventures, in 2017. Dr Laura Lane, Business Development Manager at Warwick Ventures, worked closely with Professors Nigel Dimmock and Andrew Easton to build a commercial team and secure the largest single investment into a Warwick spinout.
Warwick Ventures also helped secure translational funding from the Wellcome Trust, maintained the patents and developed the business plan that led to the investment by Abingworth.